Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Feeling tired and lonely during colder months could be seasonal depression. This condition, officially called seasonal ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

New research finds a link between strength training and a lower risk of depression. Here's how to apply the findings to your ...

"It was very surprising that a much lower dose than that recommended by WHO guidelines was still linked with lower risks of depression and depressive symptoms. This is a much more achievable MVPA ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...

Researchers determined the effect of prenatal and early postnatal lead exposure on risk for depression and anxiety in adulthood.